BRIEF published on 09/18/2024 at 07:05, 6 months 22 days ago Relief Therapeutics achève la phase clinique de l'étude RLF-OD032 Étude Clinique RLF-OD032 Biodisponibilité Phénylcétonurie Dichlorhydrate De Saproptérine
BRIEF published on 09/18/2024 at 07:05, 6 months 22 days ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 6 months 22 days ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 7 months 8 days ago Relief Therapeutics annonce la présentation des résultats de l'étude PKU GOLIKE au SSIEM 2024 Essai Clinique PKU GOLIKE THÉRAPEUTIQUE DE SECOURS SSIEM 2024 Phénylcétonurie
BRIEF published on 09/02/2024 at 07:05, 7 months 8 days ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 7 months 8 days ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 7 months 11 days ago Relief Therapeutics publie ses résultats financiers du premier semestre 2024 et une mise à jour de l'entreprise Résultats Financiers Essais Cliniques Mise À Jour De L'entreprise Augmentation Des Revenus Réserves De Trésorerie
BRIEF published on 08/30/2024 at 07:05, 7 months 11 days ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 7 months 11 days ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 8 months 5 days ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
Published on 04/10/2025 at 19:00, 1 hour 19 minutes ago D. Boral Capital Acted as Sole Bookrunner to FatPipe, Inc. (Nasdaq: FATN) in Connection with its $4.0 Million Initial Public Offering
Published on 04/10/2025 at 15:15, 5 hours 4 minutes ago ReelTime’s Reel Intelligence "RI" Outperforms AI While Requiring a Fraction of The Resources
Published on 04/10/2025 at 15:00, 5 hours 19 minutes ago Route1 Signs Significant New Orders with Major Cities in the Southwestern United States and Announces Key Corporate Updates Including Its Acquisition Growth Strategy
Published on 04/10/2025 at 15:00, 5 hours 19 minutes ago Inspire Veterinary Partners Announces Attendance at Upcoming Investor Events
Published on 04/10/2025 at 15:00, 5 hours 19 minutes ago Xebra Brands Launches National RFP to Establish Cannabis Cultivation Partnerships Across Mexico
Published on 04/10/2025 at 19:00, 1 hour 19 minutes ago Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Published on 04/10/2025 at 18:57, 1 hour 22 minutes ago EQS-Adhoc: HAMBORNER REIT AG: Adjustment of dividend strategy
Published on 04/10/2025 at 18:15, 2 hours 4 minutes ago EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma: Preliminary Q2 2025 figures exceed capital market expectations
Published on 04/10/2025 at 18:04, 2 hours 15 minutes ago Modalités de mise à disposition du Rapport sur la solvabilité et la situation financière 2024 du Groupe des Assurances du Crédit Mutuel
Published on 04/10/2025 at 18:03, 2 hours 16 minutes ago Mise à disposition des états financiers 2024 du Groupe des Assurances du Crédit Mutuel
Published on 04/10/2025 at 18:00, 2 hours 19 minutes ago SMTPC - Communiqué sur le Chiffre d'affaires du 1er trimestre 2025
Published on 04/10/2025 at 17:45, 2 hours 34 minutes ago EURAZEO INVESTIT DANS EKOSCAN INTEGRITY, ACTEUR DE REFERENCE DANS LES SOLUTIONS AVANCEES DE CONTROLE NON DESTRUCTIF POUR APPLICATIONS INDUSTRIELLES ET INFRASTRUCTURES CRITIQUES
